Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib in CCUS with IDH2 Mutations
NCT05102370Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2021
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of enasidenib in clonal cytopenia of undetermined significance (CCUS), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Best Response at 18 months. Started Oct 2021; status: completed.
02
Drugs
enasidenib
03
Conditions
clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT05102370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05102370.